Foghorn Therapeutics(US:FHTX) ZACKS·2025-03-07 00:05Company Performance - Foghorn Therapeutics Inc. reported a quarterly loss of $0.30 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.29, but an improvement from a loss of $0.57 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $2.86 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 75.63%, and down from $5.77 million in the same quarter last year [2] - Over the last four quarters, Foghorn Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates only once [2] Stock Outlook - The stock has lost approximately 1.1% since the beginning of the year, compared to a decline of 0.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $7.4 million, and for the current fiscal year, it is -$1.06 on revenues of $37.62 million [7] - The estimate revisions trend for Foghorn Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Foghorn Therapeutics belongs, is currently in the top 27% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]